Barclays PLC Purchases 2,896 Shares of SWK Holdings Co. (NASDAQ:SWKH)

Barclays PLC boosted its holdings in shares of SWK Holdings Co. (NASDAQ:SWKH) by 185.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 4,461 shares of the company’s stock after purchasing an additional 2,896 shares during the quarter. Barclays PLC’s holdings in SWK were worth $77,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Bank of New York Mellon Corp purchased a new stake in SWK during the second quarter valued at $172,000. Dimensional Fund Advisors LP grew its stake in SWK by 85.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 30,109 shares of the company’s stock worth $511,000 after acquiring an additional 13,892 shares in the last quarter. SkyView Investment Advisors LLC raised its position in SWK by 7.7% during the 2nd quarter. SkyView Investment Advisors LLC now owns 31,165 shares of the company’s stock valued at $529,000 after purchasing an additional 2,234 shares in the last quarter. Finally, Victory Capital Management Inc. purchased a new stake in SWK in the third quarter worth about $589,000. Hedge funds and other institutional investors own 99.27% of the company’s stock.

SWK Stock Performance

Shares of SWKH stock opened at $16.12 on Friday. The firm has a market cap of $197.20 million, a price-to-earnings ratio of 17.33 and a beta of 0.36. The company has a quick ratio of 5.06, a current ratio of 5.06 and a debt-to-equity ratio of 0.11. SWK Holdings Co. has a 52-week low of $15.14 and a 52-week high of $18.49. The company’s 50 day moving average is $16.16 and its 200 day moving average is $16.71.

SWK Profile

SWK Holdings Corporation, offers specialty finance and asset management services in the United States. It operates in two segments, Finance Receivables and Pharmaceutical Development. The Finance Receivables segment provides customized financing solutions to a range of life science companies, including companies in the biotechnology, medical device, medical diagnostics and related tools, animal health, and pharmaceutical industries, as well as institutions and inventors.